ECOG 2205: A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy (CRT) (IMRT permitted) with Oxaliplatin (O) and Infusional 5-Fluorouracil (5FU) Plus Cetuximab (C225) in Patients with Operable Adenocarcinoma of the Esophagus: High Risk of Post-op Adult Respiratory Distress Syndrome (ARDS)

Journal article

L.R Kleinberg, P.J Catalano, M.K Gibson, C.A Staley, E.A Montgomery, W Song, M.F Mulcahy, L.P Leichman and A.B Benson

International journal of radiation oncology, biology, physics, Vol.78(3), pp.S72-S72

2010

Metrics

1 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.95 Gastrointestinal & Esophageal Diseases; 1.95.756 Esophageal Cancer
Web Of Science research areas: Oncology; Radiology, Nuclear Medicine & Medical Imaging
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: ECOG 2205: A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy (CRT) (IMRT permitted) with Oxaliplatin (O) and Infusional 5-Fluorouracil (5FU) Plus Cetuximab (C225) in Patients with Operable Adenocarcinoma of the Esophagus: High Risk of Post-op Adult Respiratory Distress Syndrome (ARDS)
Creators: L.R Kleinberg - Johns Hopkins Hospital
P.J Catalano - Dana-Farber Cancer Institute
M.K Gibson - University of Pittsburgh
C.A Staley - Emory University
E.A Montgomery - University of Pittsburgh
W Song - Pottstown Medical Specialists
M.F Mulcahy - Northwestern University
L.P Leichman - Desert Regional Medical Center
A.B Benson - Northwestern Univ, Chicago, IL;
Publication Details: International journal of radiation oncology, biology, physics, Vol.78(3), pp.S72-S72
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Department of Pathology
Language: English
Resource Type: Journal article
Record Identifier: 991031714128802976